Drug stocks sink
Digest more
Top News
Impacts
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official, Peter Marks, had been forced to resign, the most high-profile exit at the regulator...
From USA TODAY
Biotech investors are reeling after the sudden departure of Dr. Peter Marks, a pivotal figure in the U.S. Food and Drug Administration.
From Wall Street Journal
Read more on News Digest
4d
KTVU FOX 2 on MSNDrug market sweeps yield a lot of arrests, but few prosecutions in San FranciscoLaw enforcement in San Francisco are standing by large drug market sweeps even if so far, they don't result in a lot of prosecutions.
Up to $3 billion in pharmaceuticals currently used in the United States (U.S.) depend on Canadian manufacturing, according to new research findings from the University of Toronto. Applying 25% trade tariffs to these pharmaceuticals could add $750 million in cost to the U.
The Ukrainian government has instigated rapid cost-cutting measures across the drug retail sector, triggered by reports of overpricing.
5d
Daily Post Nigeria on MSNOnitsha Drug Market: Intersociety demands urgent Commission of EnquiryA civil rights group, the International Society for Civil Liberties and Rule of Law, Intersociety, has called for urgent legislative Public Hearing and Judicial Commission of Enquiry to evidently ascertain alleged “outside-the-law” roles played by deployed field operatives of the National Agency for Food and Drug Administration and Control,
CNBC on MSN9d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure"Investors are looking for treatment options that are best in class and will secure Novo's place in the obesity drug market," Soren Lontoft, pharma equity analyst at Sydbank, told CNBC over the phone Tuesday. "We're not sure that the CagriSema is best in ...
The pre-dawn raid, touted by Mayor Daniel Lurie and the San Francisco Police Department, was part of a new “drug market crackdown.”
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday.
Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a person’s memory.